Advertisement
HomeNewsBusinessGlenmark signs cancer drug licensing deal with China's Hengrui for $18 million upfront with $1.1 billion in milestone payments

Glenmark signs cancer drug licensing deal with China's Hengrui for $18 million upfront with $1.1 billion in milestone payments

September 24, 2025 / 17:54 IST
20250924174611_20250315034541_sensex_stocks_nifty.jpg

Glenmark signs cancer drug licensing deal with China's Hengrui for $18 million upfront with $1.1 billion in milestone payments

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347